Sarepta Therapeutics’ (SRPT) Buy Rating Reiterated at Oppenheimer Holdings, Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating restated by Oppenheimer Holdings, Inc. in a report issued on Thursday. They presently have a $76.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 62.64% from the stock’s current price.
Several other analysts have also commented on SRPT. Vetr lowered Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price on the stock. in a report on Monday, May 15th. Piper Jaffray Companies set a $43.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 18th. Nomura reaffirmed a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. ValuEngine raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a report on Thursday, June 22nd. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $61.58.
Shares of Sarepta Therapeutics (SRPT) traded down 2.05% during midday trading on Thursday, hitting $45.77. The stock had a trading volume of 3,154,726 shares. The stock has a 50-day moving average price of $38.96 and a 200-day moving average price of $34.02. Sarepta Therapeutics has a 12-month low of $25.47 and a 12-month high of $63.73. The stock’s market cap is $2.94 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the previous year, the business earned ($1.19) earnings per share. The company’s revenue for the quarter was up 350000.0% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics will post ($1.17) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/07/sarepta-therapeutics-srpt-buy-rating-reiterated-at-oppenheimer-holdings-inc.html.
In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $2,050,000.00. Following the sale, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at $1,711,176. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Prentiss Smith & Co. Inc. grew its holdings in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $127,000. PNC Financial Services Group Inc. grew its holdings in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,800 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares during the period. Finally, Edge Wealth Management LLC acquired a new stake in Sarepta Therapeutics in the second quarter valued at approximately $175,000. 65.43% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.